Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + carboplatin + etoposide with or without tiragolumab in untreated extensive-stage small cell lung cancer
jRCT2080225080Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Tiragolumab + atezolizumab + carboplatin + etoposide with Placebo + atezolizumab + carboplatin + etoposide (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Feb 2020; status: completed.
02
Drugs
tiragolumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2080225080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225080.